Brief: AB Science Announces Issuance Of A Canadian Patent For Masitinib In Treatment Of ALS
01/06/2023 17:33
June 1 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR
MASITINIB
IN TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)WITH
PROTECTION UNTIL 2037
* TODAY ANNOUNCED THAT PATENT OFFICE OF CANADA HAS ISSUED A
NOTICE
OF ALLOWANCE (NOA) FOR A PATENT RELATING TO METHODS OF TREATING
AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH ITS LEAD COMPOUND
MASITINIB
* THIS NEW CANADIAN PATENT PROVIDES STRONG PROTECTION FOR
MASITINIB IN TREATMENT OF ALS UNTIL 2037 AND COMPLETES IP
COVERAGE FOR ALS ACROSS ALL KEY GEOGRAPHIC AREAS WHERE MASITINIB
COULD BE MARKETED
Source text for Eikon: ID:nGNE3cHrQL
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease